A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors

Exclusion Criteria

• •Inability to swallow medications
• •Malabsorption condition that would alter the absorption of orally administered medications
• •Poor peripheral venous access
• •Prior treatment with cobimetinib or a MEK inhibitor
• •Prior treatment with T-cell co-stimulating or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
• •Treatment with investigational therapy within 14 days prior to initiation of study treatment
• •Any anti-cancer therapy, including chemotherapy or hormonal therapy, within 2 weeks prior to initiation of study treatment
• •History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
• •Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells or any component of the atezolizumab formulation, or any component of the cobimetinib formulation
• •History of serous retinopathy, retinal vein occlusion (RVO), or evidence of ongoing serous retinopathy or RVO at baseline
• •Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
• •Uncontrolled tumor-related pain
• •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days
• •Uncontrolled hypercalcemia (ionized calcium \>1.5 millimoles per liter \[mmol/L\], calcium \>12 milligrams per deciliter \[mg/dL\], or corrected calcium greater than the upper limit of normal \[ULN\]) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy
• •Active or untreated central nervous system (CNS) metastases
• •Pregnancy or breastfeeding, or intending to become pregnant during the study
• •Cardiovascular
• •Patients who meet the following cardiovascular exclusion criterion will be excluded from study entry:
• •Left ventricular ejection fraction (LVEF) below the institutional lower limit of normal or \<50%, whichever is lower
• •Positive human immunodeficiency virus (HIV) test at screening
• •Active hepatitis B virus (HBV) infection (chronic or acute)
• •Active hepatitis C virus (HCV) infection
• •Active tuberculosis
• •Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
• •Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment